Friday Special @ The Hemp Club
Before you make a purchase, make sure you’re buying cannabis from a fully licensed and reputable dispensary…
Cannabis stocks were mostly higher on Tuesday, as investors digested the latest flurry of announcements from companies in the sector and moves among U.S. states toward legalizing weed for adult recreational use.
Aurora Cannabis Inc. shares ACB, +6.31% ACB, +6.36% rose 3%, after the company said it’s acquiring a 51% stake in Portugal’s Gaia Pharma Lda., with plans to establish a local facility to produce medical cannabis and derivative products. Terms of the deal were not disclosed.
Gaia Pharma, which just won approval to build a European Union GMP-compliant cannabis cultivation facility by the Portuguese Health Ministry, will be renamed Aurora Portugal Lda. GMP, or good manufacturing practice, is the EU standard for the authorization and licensing of food and beverages, cosmetics and pharmaceutical products.
Dr. Ethan Russo is a world-renowned authority on the medicinal use of cannabis; an academic researcher, author and industry leader whose expansive knowledge of cannabis therapeutics spans history, cultures and its myriad applications for improved health and wellbeing.
A board-certified neurologist and former Senior Medical Advisor at GW Pharmaceutics, Dr. Russo is currently Director of Research and Development of the International Cannabis and Cannabinoids Institute, a consortium of international academic institutions and private companies dedicated to promoting medical cannabis research.
The first training seminar for doctors in the field of Therapeutic hemp, part of the 2019 Czech Republic Tour has been a successful one.
Predictably, the United Nations Commission on Narcotic Drugs (CND) will not vote on the World Health Organization’s cannabis recommendations at its upcoming meeting on March 7, in Vienna.
This announcement comes as no surprise considering the release of the recommendations, on January 24, which were expected in December, were also held up.
According to the outcome of the CND’s inter-sessional meeting yesterday, posted its blog, the Expert Committee on Drug Dependence “assessed four fentanyls and five synthetic cannabinoids. Concerning the review of Cannabis, the ECDD made several recommendations including dronabinol and tinctures, among others.”
(Past news/ but highly worth a re-publishing)
Introduction: The roots of the cannabis plant have a long history of medical use stretching back millennia. How- ever, the therapeutic potential of cannabis roots has been largely ignored in modern times.
Discussion: In the first century, Pliny the Elder described in Natural Histories that a decoction of the root in water could be used to relieve stiffness in the joints, gout, and related conditions.
By the 17th century, various herbalists were recommending cannabis root to treat inflammation, joint pain, gout, and other conditions. There has been a subsequent paucity of research in this area, with only a few studies examining the composition of cannabis root and its medical potential. Active compounds identified and measured in cannabis roots include triterpenoids, friedelin (12.8 mg/kg) and epifriedelanol (21.3 mg/kg); alkaloids, cannabisativine (2.5 mg/kg) and anhydrocanna- bisativine (0.3 mg/kg); carvone and dihydrocarvone; N-( p-hydroxy-b-phenylethyl)-p-hydroxy-trans-cinnamamide (1.6mg/kg); various sterols such as sitosterol (1.5%), campesterol (0.78%), and stigmasterol (0.56%); and other minor compounds, including choline.
Of note, cannabis roots are not a significant source of D9- tetrahydrocannabinol (THC), cannabidiol, or other known phytocannabinoids.
Conclusion: The current available data on the pharmacology of cannabis root components provide significant support to the historical and ethnobotanical claims of clinical efficacy. Certainly, this suggests the need for reex- amination of whole root preparations on inflammatory and malignant conditions employing modern scientific techniques.
The cannabis plant is known for its multiple uses: the leaves, flowers, seeds, stalks, and resin glands have all been exploited for food, fuel, fiber, medicine, and other uses. One of the first mentions of the medical use of cannabis root was by the Roman historian, Pliny the Elder, who wrote in his Natural Histories that ‘‘a decoction of the root in water relaxes contrac- tions of the joints and cures gout and similar maladies.’’1 By the latter part of 17th century, various physicians and herbalists recommended cannabis root to treat fever,2,3 inflammation,4–9 gout, arthritis, and joint pain,1,5,6,8,10– 12 as well as skin burns5,8,10 and hard tumors.6–8 There
1Ryz Re ́mi, Vancouver, Canada. 2PHYTECS, Los Angeles, California.